Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58.

Haller PM, Wiviott SD, Berg DD, Jarolim P, Goodrich EL, Bhatt DL, Gause-Nilsson I, Leiter LA, McGuire DK, Wilding JPH, Raz I, Sabatine MS, Morrow DA

Open source

DOI: 10.1002/ehf2.15415
Published: 2025 Dec
Container: ESC heart failure
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ehf2.15415,
  title = {Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58.},
  author = {Haller PM and Wiviott SD and Berg DD and Jarolim P and Goodrich EL and Bhatt DL and Gause-Nilsson I and Leiter LA and McGuire DK and Wilding JPH and Raz I and Sabatine MS and Morrow DA},
  year = {2025},
  journal = {ESC heart failure},
  doi = {10.1002/ehf2.15415},
  url = {https://doi.org/10.1002/ehf2.15415}
}

RIS

TY  - JOUR
TI  - Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58.
AU  - Haller PM
AU  - Wiviott SD
AU  - Berg DD
AU  - Jarolim P
AU  - Goodrich EL
AU  - Bhatt DL
AU  - Gause-Nilsson I
AU  - Leiter LA
AU  - McGuire DK
AU  - Wilding JPH
AU  - Raz I
AU  - Sabatine MS
AU  - Morrow DA
PY  - 2025
JO  - ESC heart failure
DO  - 10.1002/ehf2.15415
UR  - https://doi.org/10.1002/ehf2.15415
ER  -

APA

PM, H., SD, W., DD, B., P, J., EL, G., DL, B., I, G., LA, L., DK, M., JPH, W., I, R., MS, S., & DA, M. (2025). Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58.. ESC heart failure. https://doi.org/10.1002/ehf2.15415

Source records

pubmed · retrieved 2026-09-26T23:14:45.451Z